22nd Century Group (XXII) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
19 Dec, 2025Executive summary
Special Meeting scheduled for February 20, 2026, to vote on five key proposals impacting capital structure and compliance with Nasdaq rules.
Proposals include a reverse stock split, approval of Series A Preferred anti-dilution provisions, warrant amendments, a potential new offering, and possible adjournment to solicit more votes.
Board recommends voting in favor of all proposals to maintain Nasdaq listing and support future capital raising.
Voting matters and shareholder proposals
Proposal 1: Reverse stock split at a ratio between 1-for-2 and 1-for-200, at Board's discretion, to comply with Nasdaq minimum bid price requirements.
Proposal 2: Approval of Series A Preferred anti-dilution provisions, potentially allowing conversion below Nasdaq Minimum Price, subject to a floor price.
Proposal 3: Amendment to August 2025 warrants to add anti-dilution provisions, potentially issuing more than 19.99% of common stock at below Minimum Price.
Proposal 4: Approval for a potential future offering of up to $20 million in new convertible preferred stock and warrants, with similar anti-dilution features.
Proposal 5: Adjournment of the meeting if necessary to solicit additional proxies for the above proposals.
Board of directors and corporate governance
Board retains discretion to implement or abandon the reverse split within 24 months of approval.
Board recommends all proposals and will bear costs of proxy solicitation.
Stockholder proposals for the next annual meeting must be received by February 2, 2026, and comply with SEC rules.
Latest events from 22nd Century Group
- Revenue grew, losses narrowed, but going concern risk persists as VLN rebranding continues.XXII
Q2 20241 Feb 2026 - Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 2024 revenue dropped 24.5% with ongoing losses, but net debt and cost structure improved.XXII
Q3 202414 Jan 2026 - Key votes include a reverse split, preferred stock, warrant changes, and a new offering.XXII
Proxy Filing30 Dec 2025 - VLN relaunch, FDA compliance, and CMO focus drive 2025 growth after 2024 turnaround.XXII
Q4 202426 Dec 2025 - Relaunching low-nicotine brands, expanding retail reach, and targeting profitability by Q4 2025.XXII
Emerging Growth Conference26 Dec 2025 - Resale of 1.4M shares enables debt settlement for a tobacco innovator with FDA-authorized VLN products.XXII
Registration Filing16 Dec 2025 - Registering 104,124 shares for resale, with no proceeds to the company and ongoing financial risks.XXII
Registration Filing16 Dec 2025 - Registering 93.6M shares for resale; proceeds only from warrant exercises; faces losses and regulatory risks.XXII
Registration Filing16 Dec 2025